Valuation: Agenus Inc.

Market Cap 285M 254M 235M 213M 399M 27.05B 405M 2.83B 1.12B 14.17B 1.07B 1.05B 44.69B P/E 2026 *
25.7x
P/E 2027 * -13.4x
Enterprise Value 285M 254M 235M 213M 399M 27.05B 405M 2.83B 1.12B 14.17B 1.07B 1.05B 44.69B EV / Sales 2026 *
2.28x
EV / Sales 2027 * 2.46x
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -
1 day-2.76%
1 week+4.80%
Current month-36.25%
1 month-25.53%
3 months+5.85%
6 months+62.31%
Current year+101.59%
1 week 6.05
Extreme 6.05
6.58
1 month 6
Extreme 6
10.31
Current year 2.71
Extreme 2.71
10.31
1 year 2.71
Extreme 2.71
10.31
3 years 1.38
Extreme 1.38
19.69
5 years 1.38
Extreme 1.38
93.8
10 years 1.38
Extreme 1.38
135.8
Manager TitleAgeSince
Chief Executive Officer 73 30/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/10/2021
Director TitleAgeSince
Chairman 73 03/11/2010
Director/Board Member 68 07/03/2007
Director/Board Member 68 06/12/2006
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Director

1,179 0.0026%
01/10/26 Free

Director

4,443 0.0098%
10/08/26 Free

Chief Executive Officer

1,971,500 4.4054%
Change 5-day change 1-year change 3-year change Capi.($)
-2.76%+4.80%+52.90%-58.06% 285M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average -0.03%+1.92%+48.56%+120.99% 38.34B
Weighted average by Cap. +0.39%+2.73%+46.02%+142.69%

Financials

2026 *2027 *
Net sales 125M 112M 103M 93.6M 175M 11.89B 178M 1.24B 492M 6.23B 470M 460M 19.63B 116M 104M 95.67M 86.7M 162M 11.01B 165M 1.15B 456M 5.77B 435M 426M 18.18B
Net income 39.4M 35.18M 32.5M 29.46M 55.11M 3.74B 56.02M 391M 155M 1.96B 148M 145M 6.18B -28.55M -25.5M -23.55M -21.34M -39.93M -2.71B -40.59M -283M -112M -1.42B -107M -105M -4.48B
Net Debt - -
Projected Income Statement - Annual - Agenus Inc.
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
23/10/26 US$6.330 -2.76% 510,514
22/10/26 US$6.510 +1.72% 553,954
21/10/26 US$6.400 -0.31% 789,683
20/10/26 US$6.420 +3.88% 827,183
19/10/26 US$6.180 +2.32% 734,955
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Agenus Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.330USD
Average target price
26.33USD
Spread / Average Target
+316.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Agenus Inc.
  1. Stock Market
  2. Stocks
  3. AGEN Stock